Representative images of MDA-MB-231 breast cancer cell colonies. A Cells with 3 µM of Dox B cells with 50 µM of rhoifolin (Rh) C cells treated with a combination (COMB) of 3 µM Dox and 50 µM rhoifolin, and D cells treated with vehicle (control; CNT). The experiment was conducted in triplicate.

 
 
  Part of: Al-Radaideh AS, Abbas MA, Al-Kabariti AY, Alqaraleh M, Madi R, Obeidat R (2025) Rhoifolin potentiates the anti-cancer activity of doxorubicin in MDA-MB-231 triple-negative breast cancer cells. Pharmacia 72: 1-9. https://doi.org/10.3897/pharmacia.72.e148600